Institution
Memorial Sloan Kettering Cancer Center
Healthcare•New York, New York, United States•
About: Memorial Sloan Kettering Cancer Center is a healthcare organization based out in New York, New York, United States. It is known for research contribution in the topics: Cancer & Population. The organization has 30293 authors who have published 65381 publications receiving 4462534 citations. The organization is also known as: MSKCC & New York Cancer Hospital.
Topics: Cancer, Population, Breast cancer, Radiation therapy, Prostate cancer
Papers published on a yearly basis
Papers
More filters
TL;DR: It is confirmed that mortality from invasive aspergillosis in severely immunosuppressed patients remains high even with standard amphotericin B, and new approaches and new therapies are needed to improve the outcome.
778 citations
TL;DR: With knowledge cemented in decades of research into tumour-initiating events, current experimental and conceptual models are beginning to address the genetic basis for cancer colonization of distant organs.
Abstract: Metastasis can be viewed as an evolutionary process, culminating in the prevalence of rare tumour cells that overcame stringent physiological barriers as they separated from their original environment and developmental fate. This phenomenon brings into focus long-standing questions about the stage at which cancer cells acquire metastatic abilities, the relationship of metastatic cells to their tumour of origin, the basis for metastatic tissue tropism, the nature of metastasis predisposition factors and, importantly, the identity of genes that mediate these processes. With knowledge cemented in decades of research into tumour-initiating events, current experimental and conceptual models are beginning to address the genetic basis for cancer colonization of distant organs.
777 citations
Harvard University1, Medical University of Vienna2, Institut Jules Bordet3, University of St. Gallen4, Kantonsspital St. Gallen5, Institut Gustave Roussy6, Memorial Sloan Kettering Cancer Center7, Karolinska Institutet8, University of Bordeaux9, University of North Carolina at Chapel Hill10, Queen Mary University of London11, Charité12, Marmara University13, Mount Sinai Hospital, Toronto14, Ludwig Maximilian University of Munich15, University of Michigan16, National Taiwan University17, University of Ulm18, National Institutes of Health19, Gdańsk Medical University20, Sahlgrenska University Hospital21, Baylor College of Medicine22, University of Toronto23, Netherlands Cancer Institute24, Paracelsus Private Medical University of Salzburg25, Fudan University26, The Royal Marsden NHS Foundation Trust27, Kyoto University28, Institute of Cancer Research29, University of Milan30, McMaster University31
TL;DR: The 15th St. Gallen International Breast Cancer Conference 2017 in Vienna, Austria reviewed substantial new evidence on loco-regional and systemic therapies for early breast cancer, and recommended bisphosphonate use in postmenopausal women to prevent breast cancer recurrence.
777 citations
TL;DR: Stricker et al. as discussed by the authors performed whole-exome sequencing of 86 matched brain metastases, primary tumors, and normal tissue and found potentially clinically informative alterations in the brain metastasis not detected in the matched primary-tumor sample.
Abstract: Brain metastases are associated with a dismal prognosis. Whether brain metastases harbor distinct genetic alterations beyond those observed in primary tumors is unknown. We performed whole-exome sequencing of 86 matched brain metastases, primary tumors, and normal tissue. In all clonally related cancer samples, we observed branched evolution, where all metastatic and primary sites shared a common ancestor yet continued to evolve independently. In 53% of cases, we found potentially clinically informative alterations in the brain metastases not detected in the matched primary-tumor sample. In contrast, spatially and temporally separated brain metastasis sites were genetically homogenous. Distal extracranial and regional lymph node metastases were highly divergent from brain metastases. We detected alterations associated with sensitivity to PI3K/AKT/mTOR, CDK, and HER2/EGFR inhibitors in the brain metastases. Genomic analysis of brain metastases provides an opportunity to identify potentially clinically informative alterations not detected in clinically sampled primary tumors, regional lymph nodes, or extracranial metastases.
Significance: Decisions for individualized therapies in patients with brain metastasis are often made from primary-tumor biopsies. We demonstrate that clinically actionable alterations present in brain metastases are frequently not detected in primary biopsies, suggesting that sequencing of primary biopsies alone may miss a substantial number of opportunities for targeted therapy. Cancer Discov; 5(11); 1164–77. ©2015 AACR .
See related commentary by Stricker and Arteaga, [p. 1124][1] .
This article is highlighted in the In This Issue feature, [p. 1111][2]
[1]: /lookup/volpage/5/1124?iss=11
[2]: /lookup/volpage/5/1111?iss=11
776 citations
TL;DR: This study establishes ATO as a highly effective therapy for patients with relapsed APL as well as establishing its use as a maintenance therapy.
Abstract: PURPOSE: To determine the safety and efficacy of arsenic trioxide (ATO) in patients with relapsed acute promyelocytic leukemia (APL). PATIENTS AND METHODS: Forty patients experiencing first (n = 21) or ≥ second (n = 19) relapse were treated with daily infusions of ATO to a maximum of 60 doses or until all leukemic cells in bone marrow were eliminated. Patients who achieved a complete remission (CR) were offered one consolidation course of ATO that began 3 to 4 weeks later. Patients who remained in CR were eligible to receive further cycles of ATO therapy on a maintenance study. RESULTS: Thirty-four patients (85%) achieved a CR. Thirty-one patients (91%) with CRs had posttreatment cytogenetic tests negative for t(15;17). Eighty-six percent of the patients who were assessable by reverse transcriptase polymerase chain reaction converted from positive to negative for the promyelocytic leukemia/retinoic acid receptor-alpha transcript by the completion of their consolidation therapy. Thirty-two patients receive...
775 citations
Authors
Showing all 30708 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Gordon H. Guyatt | 231 | 1620 | 228631 |
| Edward Giovannucci | 206 | 1671 | 179875 |
| Irving L. Weissman | 201 | 1141 | 172504 |
| Craig B. Thompson | 195 | 557 | 173172 |
| Joan Massagué | 189 | 408 | 149951 |
| Gad Getz | 189 | 520 | 247560 |
| Chris Sander | 178 | 713 | 233287 |
| Richard B. Lipton | 176 | 2110 | 140776 |
| Richard K. Wilson | 173 | 463 | 260000 |
| George P. Chrousos | 169 | 1612 | 120752 |
| Stephen J. Elledge | 162 | 406 | 112878 |
| Murray F. Brennan | 161 | 925 | 97087 |
| Lewis L. Lanier | 159 | 554 | 86677 |
| David W. Bates | 159 | 1239 | 116698 |
| Dan R. Littman | 157 | 426 | 107164 |